Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTIX is 0.51M, and currently, shorts hold a 3.32% of that float. The average trading volume for PTIX on May 12, 2025 was 440.98K shares.
PTIX) stock’s latest price update
Protagenic Therapeutics Inc (NASDAQ: PTIX)’s stock price has dropped by -11.14 in relation to previous closing price of 3.50. Nevertheless, the company has seen a loss of -0.78% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-29 that Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (“Protagenic Therapeutics” or the “Company”), a leader in biopharmaceutical innovation, today announced that the Company’s Board of Directors has approved a 1-for-14 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) to be effective 12:01 a.m., Eastern Time, on May 5, 2025.
PTIX’s Market Performance
Protagenic Therapeutics Inc (PTIX) has experienced a -0.78% fall in stock performance for the past week, with a -16.80% drop in the past month, and a -18.63% drop in the past quarter. The volatility ratio for the week is 26.34%, and the volatility levels for the past 30 days are at 15.21% for PTIX. The simple moving average for the past 20 days is -6.32% for PTIX’s stock, with a -54.73% simple moving average for the past 200 days.
PTIX Trading at -16.24% from the 50-Day Moving Average
After a stumble in the market that brought PTIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.12% of loss for the given period.
Volatility was left at 15.21%, however, over the last 30 days, the volatility rate increased by 26.34%, as shares sank -14.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.89% lower at present.
During the last 5 trading sessions, PTIX fell by -0.78%, which changed the moving average for the period of 200-days by -68.32% in comparison to the 20-day moving average, which settled at $3.32. In addition, Protagenic Therapeutics Inc saw -54.66% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTIX
Current profitability levels for the company are sitting at:
- -226.74 for the present operating margin
The net margin for Protagenic Therapeutics Inc stands at -219.76. The total capital return value is set at -5.63. Equity return is now at value -236.06, with -175.99 for asset returns.
Currently, EBITDA for the company is -5.48 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of -0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.
Conclusion
In conclusion, Protagenic Therapeutics Inc (PTIX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
